900th hospital of the joint logistics team, PLA
Welcome,         Profile    Billing    Logout  
 0 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LIN, SHAOJUN
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
3
212
RoW
PD-1 blocking antibody, JS001, GP, IMRT
Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
12/25
12/28
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
3
212
RoW
Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/27
NCT06095154: CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma

Recruiting
3
474
RoW
CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V8 Stage
12/27
12/30
NCT06775756: Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Not yet recruiting
3
474
NA
IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
04/27
04/30
NCT05519956: Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Not yet recruiting
3
398
NA
level Ib-covering IMRT, level Ib-sparing IMRT
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
09/25
09/25
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Recruiting
3
200
RoW
PD-1 antibody, Gemcitabine, Cisplatin, IMRT
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
03/26
03/26
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recruiting
2
67
RoW
Nimotuzumab, Radiation
Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital
Recurrent Nasopharyngeal Carcinoma
04/20
11/22
NCT04421469: Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Not yet recruiting
2
39
RoW
Triprilimab(JS001)
Fujian Cancer Hospital, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
04/23
06/23
NCT04220528: Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

Recruiting
2
129
RoW
Capecitabine/Tiggio, Radiation
Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/23
12/23
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting
2
200
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumor
12/23
06/24
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma

Recruiting
2
63
RoW
consolidative radiotherapy, local consolidative radiotherapy
Jiangxi Provincial Cancer Hospital
Oligometastatic Disease
05/25
05/26
NCT04745741: Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Not yet recruiting
N/A
200
RoW
IB-positive group
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
05/21
06/21
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Recruiting
N/A
214
RoW
Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin
Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University
Nasopharyngeal Carcinoma, Nutritional Support
07/25
09/25
NCT06136962: Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Not yet recruiting
N/A
500
RoW
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
12/24
12/24
fu, zhichao
NCT04741490: Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Recruiting
N/A
20
RoW
Camrelizumab, radiotherapy
Fuzhou General Hospital
Esophageal Squamous Cell Carcinomas
08/22
08/23
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Recruiting
N/A
214
RoW
Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin
Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University
Nasopharyngeal Carcinoma, Nutritional Support
07/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LIN, SHAOJUN
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
3
212
RoW
PD-1 blocking antibody, JS001, GP, IMRT
Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
12/25
12/28
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
3
212
RoW
Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/27
NCT06095154: CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma

Recruiting
3
474
RoW
CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V8 Stage
12/27
12/30
NCT06775756: Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Not yet recruiting
3
474
NA
IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
04/27
04/30
NCT05519956: Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Not yet recruiting
3
398
NA
level Ib-covering IMRT, level Ib-sparing IMRT
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
09/25
09/25
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Recruiting
3
200
RoW
PD-1 antibody, Gemcitabine, Cisplatin, IMRT
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
03/26
03/26
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recruiting
2
67
RoW
Nimotuzumab, Radiation
Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital
Recurrent Nasopharyngeal Carcinoma
04/20
11/22
NCT04421469: Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Not yet recruiting
2
39
RoW
Triprilimab(JS001)
Fujian Cancer Hospital, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
04/23
06/23
NCT04220528: Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

Recruiting
2
129
RoW
Capecitabine/Tiggio, Radiation
Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/23
12/23
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting
2
200
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumor
12/23
06/24
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma

Recruiting
2
63
RoW
consolidative radiotherapy, local consolidative radiotherapy
Jiangxi Provincial Cancer Hospital
Oligometastatic Disease
05/25
05/26
NCT04745741: Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Not yet recruiting
N/A
200
RoW
IB-positive group
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
05/21
06/21
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Recruiting
N/A
214
RoW
Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin
Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University
Nasopharyngeal Carcinoma, Nutritional Support
07/25
09/25
NCT06136962: Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Not yet recruiting
N/A
500
RoW
Fujian Cancer Hospital
Nasopharyngeal Carcinoma
12/24
12/24
fu, zhichao
NCT04741490: Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Recruiting
N/A
20
RoW
Camrelizumab, radiotherapy
Fuzhou General Hospital
Esophageal Squamous Cell Carcinomas
08/22
08/23
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Recruiting
N/A
214
RoW
Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin
Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University
Nasopharyngeal Carcinoma, Nutritional Support
07/25
09/25

Download Options